Key result
Cardiomyocyte STC1 limits post-ischemia-reperfusion fibrosis and improves cardiac function by targeting the DOCK1/RAC1 axis.
Why the study?
Cardiac fibrosis drives heart failure after ischemia-reperfusion injury, but the role of stanniocalcin-1 in myocardial fibrosis remains unexplored.
Does STC1 overexpression or knockdown alter cardiac fibrosis and function in a mouse model of myocardial ischemia-reperfusion injury?
Does STC1 overexpression or knockdown alter cardiac fibrosis and function in a mouse model of myocardial ischemia-reperfusion injury?
STC1 acts as an endogenous antifibrotic factor by disrupting the DOCK1/RAC1-GTP signaling axis, highlighting a potential therapeutic target for ischemic heart failure.
BACKGROUND: Cardiac fibrosis is a pivotal pathological process driving heart failure following ischemia-reperfusion (I/R) injury. STC1 (stanniocalcin-1), a conserved glycoprotein with mitochondrial regulatory functions, remains unexplored in myocardial fibrosis. This study investigates the mechanistic role of cardiomyocyte-derived STC1 in cardiac fibrosis. METHODS: Mouse models of myocardial I/R injury were established by left anterior descending coronary artery ligation followed by 24-hour reperfusion. Cardiac-specific STC1 knockdown (adeno-associated virus 9-shSTC1) or overexpression (adeno-associated virus 9-STC1) preceded I/R injury induction. Cardiac function was assessed via echocardiography, and fibrosis was quantified histologically (Masson's trichrome, Sirius red) and molecularly (α-SMA [alpha smooth muscle actin], COL1A1 [collagen type I alpha 1 chain], COL3A1 [collagen type III alpha 1 chain], Smad2 [SMAD family member 2]). In vitro, cardiomyocyte-derived conditioned medium was applied to TGF-β (transforming growth factor beta)-stimulated fibroblasts, supplemented with recombinant STC1 for rescue assays. Protein-protein interactions were analyzed via coimmunoprecipitation and domain-deletion mutants. RESULTS: STC1 deficiency exacerbated post-I/R cardiac dysfunction and fibrosis, accompanied by elevated α-SMA, COL1A1, and phosphorylated-Smad2 levels. Conversely, STC1 overexpression attenuated I/R-induced functional decline and fibrosis. In addition, cardiomyocyte-derived STC1 suppressed TGF-β-driven fibroblast activation and Smad2 nuclear translocation. Mechanistically, STC1 directly interacted with the DOCKER domain of DOCK1 (dedicator of cytokinesis 1), disrupting DOCK1/RAC1-GTP (Rac family small GTPase 1 bound to guanosine triphosphate) signaling. Genetic ablation of the DOCKER domain abolished STC1's antifibrotic effects, restoring RAC1-GTP activity and fibrosis markers. CONCLUSIONS: Cardiomyocyte-derived STC1 mitigates cardiac fibrosis post I/R by targeting the DOCK1/RAC1 axis via its interaction with the DOCKER domain. These findings identify STC1-DOCK1 as a novel therapeutic pathway for ischemic heart failure.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Myocardial ischemia-reperfusion (I/R) injury (n=120). STC1 overexpression (AAV9-STC1) or knockdown (AAV9-shSTC1) vs. AAV9-shNC, AAV9-empty vector, or sham surgery was evaluated on Cardiac function (ejection fraction and fractional shortening) and myocardial fibrosis (p=<0.05). Cardiomyocyte-derived STC1 mitigated cardiac fibrosis and improved cardiac function post ischemia-reperfusion injury by targeting the DOCK1/RAC1 axis via interaction with the DOCKER domain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: